Home Cart Sign in  
Chemical Structure| 4871-97-0 Chemical Structure| 4871-97-0

Structure of Curcumol
CAS No.: 4871-97-0

Chemical Structure| 4871-97-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Curcumol is a sesquiterpene originally isolated from curcuma rhizomes showing anticancer activities both in vitro and in vivo.

Synonyms: (-)-Curcumol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Curcumol

CAS No. :4871-97-0
Formula : C15H24O2
M.W : 236.35
SMILES Code : O[C@@]1(C2)[C@H](C(C)C)C[C@]3(O1)[C@@H](C)CC[C@@]3([H])C2=C
Synonyms :
(-)-Curcumol
MDL No. :MFCD00272163
InChI Key :QRMPRVXWPCLVNI-YYFQZIEXSA-N
Pubchem ID :14240392

Safety of Curcumol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • JAK2

In Vitro:

Cell Line
Concentration Treated Time Description References
LO2 cells 15, 30, 60 μM 24 h Curcumol significantly alleviated PA-induced damage in LO2 cells, reduced lipid accumulation, and inhibited the expression of cellular senescence markers. PMC8450123
primary microglia 0.1 g/L or 0.3 g/L 72 h Curcumol treatment reduced the percentage of CD11b+Iba1+CD16+ and CD11b+Iba1+CD86+ M1 microglia and increased the percentage of CD11b+Iba1+CD163+ and CD11b+Iba1+CD206+ M2 microglia, indicating that Curcumol promoted anti-inflammatory M2 microglial polarization. PMC11196256
C666-1 cells 100 µg/mL 24 h To investigate the inhibitory effect of Curcumol on nasopharyngeal carcinoma cells, the results showed that Curcumol significantly inhibited the invasion and migration of C666-1 cells. PMC11430640
Primary microglia 0.1 g/L or 0.3 g/L 72 h Curcumol induced anti-inflammatory M2 microglial polarization, reduced the production of pro-inflammatory cytokines, and protected neurons from apoptosis. PMC11196256
K7M2 WT cells 0-500 nM 72 h Curcumol inhibited K7M2 WT cell proliferation in a dose-dependent manner PMC9318016
K7M2 WT cells 100 nM 48 h Curcumol combined with CDDP significantly increased apoptosis in K7M2 WT cells PMC9318016
U2OS cells 37.67 nM 72 h Curcumol combined with CDDP significantly inhibited U2OS cell proliferation PMC9318016
MG63 cells 41.41 nM 72 h Curcumol combined with CDDP significantly inhibited MG63 cell proliferation PMC9318016
KHOS cells 28.3 nM 72 h Curcumol combined with CDDP significantly inhibited KHOS cell proliferation PMC9318016
HSC-LX2 cells 30 μM 24 h Curcumol upregulates the phosphorylation levels of RIPK1 and RIPK3, promotes their aggregation to form necrosome in HSCs, and eventually induces HSC necroptosis. PMC6142373
LO2 cells 15, 30, 60 μM 24 h Curcumol was capable of ameliorating ethanol-induced cell damage and effectively suppressed ethanol-induced lipid accumulation and cellular senescence in LO2 cells. PMC9273900

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
LVG Golden Syrian hamsters High-fat diet-induced NAFLD model Oral gavage 15, 30, 60 mg/kg Once daily for 4 weeks Curcumol significantly improved liver injury and steatosis induced by a high-fat diet and inhibited hepatocyte senescence. PMC8450123
Rats Sprague Dawley (SD) rats Oral and intravenous 10, 40, 80 mg/kg (oral), 2.0 mg/kg (intravenous) Single dose To investigate the pharmacokinetics, tissue distribution, and plasma protein binding rate of curcumol in rats. Results indicated that curcumol was rapidly absorbed and eliminated in rats, with oral bioavailability ranging from 9.2% to 13.1%. The maximum concentration of curcumol was observed in most organs within 0.5-1.0 hours, with high accumulation in the small intestine, colon, liver, and kidney. The plasma protein binding rate ranged from 85.6% to 93.4%. PMC9748077
C57BL/6 mice middle cerebral artery occlusion (MCAO) model intraperitoneal injection 0.1 g/kg or 0.3 g/kg once daily for 7 days Curcumol treatment reduced infarct volume, attenuated neuronal damage and inflammation, and improved motor function recovery in MCAO mice. Curcumol also promoted anti-inflammatory M2 microglial polarization in vivo and reduced local T cell infiltration, impairing the Treg/Th17 balance. PMC11196256
BALB/c nude mice Nasopharyngeal carcinoma xenograft model Gavage 80 mg/kg Once daily for 2 weeks To investigate the inhibitory effect of Curcumol on nasopharyngeal carcinoma xenografts in vivo, the results showed that Curcumol significantly inhibited tumor growth and reduced the expression of UBE2C. PMC11430640
C57BL/6 mice Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 0.1 g/kg or 0.3 g/kg Once daily for 7 days Curcumol reduced infarct volume, attenuated neuronal damage and neuroinflammation, and improved motor function recovery in MCAO mice. Additionally, Curcumol promoted anti-inflammatory M2 microglial polarization and modulated Treg/Th17 balance. PMC11196256
BALB/c mice K7M2 WT orthotopic transplantation model Curcumol: oral, CDDP: intraperitoneal 30 mg/kg Curcumol: daily, CDDP: once per week, for 31 days Curcumol combined with CDDP significantly inhibited tumor growth and reduced M2-type macrophage recruitment PMC9318016
ICR mice CCl4-induced liver fibrosis model Intraperitoneal injection 15, 30, 60 mg/kg Every other day for 5-8 weeks Curcumol ameliorates CCl4-induced liver fibrosis in mice by inducing RIPK1/RIPK3 complex-dependent necroptosis. PMC6142373
C57BL/6J mice Alcoholic fatty liver disease model Oral 30, 45, 60 mg/kg Once daily for 30 days Curcumol alleviated ethanol-induced liver injury and lipid deposition, and effectively inhibited hepatocyte senescence. PMC9273900

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.23mL

0.85mL

0.42mL

21.16mL

4.23mL

2.12mL

42.31mL

8.46mL

4.23mL

References

[1]Tang QL, Guo JQ, et al. Curcumol induces apoptosis in SPC-A-1 human lung adenocarcinoma cells and displays anti-neoplastic effects in tumor bearing mice. Asian Pac J Cancer Prev. 2015;16(6):2307-12.

[2]Zhang W, Wang Z, et al. Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells. Med Oncol. 2011 Mar;28(1):307-14.

[3]Wei W, Rasul A, Sadiqa A, Sarfraz I, Hussain G, Nageen B, Liu X, Watanabe N, Selamoglu Z, Ali M, Li X, Li J. Curcumol: From Plant Roots to Cancer Roots. Int J Biol Sci. 2019 Jun 4;15(8):1600-1609

[4]Liu H, Wang J, Tao Y, Li X, Qin J, Bai Z, Chi B, Yan W, Chen X. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/Akt pathways. Life Sci. 2019 Mar 15;221:354-361

[5]Huang X, Qian J, Li L, Zhang X, Wei G, Lv J, Qin F, Yu J, Xiao Y, Gong Z, Huo J. Curcumol improves cisplatin sensitivity of human gastric cancer cells through inhibiting PI3K/AKT pathway. Drug Dev Res. 2020 Jul 26

[6]Zuo HX, Jin Y, Wang Z, Li MY, Zhang ZH, Wang JY, Xing Y, Ri MH, Jin CH, Xu GH, Piao LX, Ma J, Jin X. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer. J Ethnopharmacol. 2020 Jul 15;257:112835

[7]Ning N, Liu S, Liu X, Tian Z, Jiang Y, Yu N, Tan B, Feng H, Feng X, Zou L. Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways. J Cancer. 2020 Jan 14;11(7):1679-1692

 

Historical Records

Categories